All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • Market intelligence reports
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 15, 2019
Home » Quality of life and quality of studies take stage as Takeda reports solid NSCLC findings
Looking to read the full article? Subscribe to BioWorld Asia.
ESMO Asia 2019

Quality of life and quality of studies take stage as Takeda reports solid NSCLC findings

November 26, 2019
By David Ho
No Comments
SINGAPORE – Takeda Pharmaceutical Co. Ltd. presented new findings from its phase III ALTA-1L trial evaluating its Alunbrig (brigatinib) vs. crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) who had not received a prior ALK inhibitor, showing Alunbrig reduced the risk of disease progression or death by 76% after more than two years of follow-up.
BioWorld Asia Cancer Clinical Conferences

Already a subscriber? Sign in 

Popular Stories

  • Bioworld MedTech’s Oncology Extra

    BioWorld MedTech
    Keeping you up to date on recent developments in oncology.
  • Ear-disorders

    FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

    BioWorld MedTech
    The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
  • Drugs-pills-global-map-

    Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

    BioWorld
    LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
  • Frankyoung-11-27

    Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

    BioWorld
    Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
  • Biopharma companies continue their strong momentum in November

    BioWorld
    After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Archives
    • Contact us
    • Cookie policy
    • Copyright notice
    • Privacy policy
    • Share your news
    • Staff
    • Terms of use
Follow Us

Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing